Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
The Ted Rogers Centre is committed to enabling equitable access to quality, person-centred heart failure care. To this end, we develop digital health solutions that are precise and predictive, and empower Canadians with heart failure to stay safe and well-managed at home.
Our revolutionary technology enables continuous monitoring and proactive, remote support so that clinicians and patients can take action before symptoms worsen. “Medly” is a remote management program where patients enter their symptoms, receive real-time feedback on self-care, medications are adjusted, and clinical teams are alerted to any urgent issues that require follow up.
Medly keeps patients safe at home, guarded by specialized care for which they’d otherwise need to visit clinics.
Medly is the first telemonitoring system to be designated a Class II medical device by Health Canada. Inside University Health Network, it has proven to cut rehospitalizations by 50% and all-cause admissions by 24% for people with heart failure.
Medly is being deployed in specialty cardiac centres and primary care clinics across Ontario. Medly Therapeutics is working with institutions to see how the technology can fit in their workflows.
Any interested clinicians may reach out to the Medly team to learn more about the successful model, best practices, and details on implementation.
